Effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in postmenopausal women with spondylosis

Naohisa Miyakoshi, Yoichi Shimada, Shigeru Ando, Takashi Minato, Eiji Itoi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Osteoporosis and spondylosis often occur simultaneously. However, there are no previous reports about the effects of osteoporosis medication on incidence of vertebral fractures in people with spondylosis. In this study, we conducted a retrospective investigation of the effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in women with spondylosis. The present subjects were 101 postmenopausal women with osteoporosis aged >60 years, divided into three groups: D group (n = 45), treated for >5 years with alfacalcidol; D+ECT group (n = 26), treated for >5 years with alfacalcidol plus elcatonin; control group (n = 30), who received no medications for >5 years. Over the 5-year treatment period, bone mineral density (BMD) of the lumbar spine and proximal femur did not significantly change in the D and D+ECT groups, but they significantly decreased in the control group (P < 0.05). The number of incident vertebral fractures per patient was significantly higher in the control group (2.9) than in the D group (1.2) and D+ECT group (1.5) (P < 0.01). There was no significant difference in BMD or incident vertebral fractures between the D and D+ECT groups. In all three groups, the number of incident vertebral fractures positively correlated with the number of prevalent vertebral fractures (0.303 ≤ r ≤ 0.434), and negatively correlated with baseline BMD (-0.703 ≤ r ≤ -0.326) and the osteophyte score representing the degree of spondylosis (-0.769 ≤ r ≤ -0.365). Further multiple regression analysis revealed that the medication (D or D+ECT, P < 0.001) and the osteophyte score (P < 0.001) were the most significant contributors for the number of incident vertebral fractures. In conclusion, elcatonin had no additive effects on BMD or prevention of vertebral fractures in postmenopausal women receiving alfacalcidol. Presence of spondylosis (indicated by a high osteophyte score) appears to have an effect on prevention of vertebral fractures.

Original languageEnglish
Pages (from-to)491-497
Number of pages7
JournalJournal of Bone and Mineral Metabolism
Volume24
Issue number6
DOIs
Publication statusPublished - 2006 Nov 1
Externally publishedYes

Keywords

  • Alfacalcidol
  • Elcatonin
  • Osteoporosis
  • Spondylosis
  • Vertebral fracture

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Fingerprint Dive into the research topics of 'Effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in postmenopausal women with spondylosis'. Together they form a unique fingerprint.

Cite this